These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 33044184)
1. Cognitive Impairment, P300, and Transforming Growth Factor β1 in Different Forms of Dementia. Khedr EM; Gomaa AMS; Ahmed OG; Sayed HMM; Gamea A J Alzheimers Dis; 2020; 78(2):837-845. PubMed ID: 33044184 [TBL] [Abstract][Full Text] [Related]
2. Electrophysiological differences in cortical excitability in different forms of dementia: A transcranial magnetic stimulation and laboratory biomarkers study. Khedr EM; Ahmed OG; Sayed HM; Abo-Elfetoh N; Ali AM; Gomaa AM Neurophysiol Clin; 2020 Jul; 50(3):185-193. PubMed ID: 32591186 [TBL] [Abstract][Full Text] [Related]
3. Serum uric acid level and association with cognitive impairment and dementia: systematic review and meta-analysis. Khan AA; Quinn TJ; Hewitt J; Fan Y; Dawson J Age (Dordr); 2016 Feb; 38(1):16. PubMed ID: 26820749 [TBL] [Abstract][Full Text] [Related]
4. Decreased serum levels of the angiogenic factors VEGF and TGF-β1 in Alzheimer's disease and amnestic mild cognitive impairment. Huang L; Jia J; Liu R Neurosci Lett; 2013 Aug; 550():60-3. PubMed ID: 23827227 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of P300 components for emotion-loaded visual event-related potential in elderly subjects, including those with dementia. Asaumi Y; Morita K; Nakashima Y; Muraoka A; Uchimura N Psychiatry Clin Neurosci; 2014 Jul; 68(7):558-67. PubMed ID: 24447302 [TBL] [Abstract][Full Text] [Related]
6. The role of human kallikrein 6, clusterin and adiponectin as potential blood biomarkers of dementia. Dukic L; Simundic AM; Martinic-Popovic I; Kackov S; Diamandis A; Begcevic I; Diamandis EP Clin Biochem; 2016 Feb; 49(3):213-8. PubMed ID: 26515085 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-18 and transforming growth factor-beta 1 plasma levels in Alzheimer's disease and vascular dementia. Malaguarnera L; Motta M; Di Rosa M; Anzaldi M; Malaguarnera M Neuropathology; 2006 Aug; 26(4):307-12. PubMed ID: 16961066 [TBL] [Abstract][Full Text] [Related]
8. Cognitive profiles and optimal cut-offs for routine cognitive tests in elderly individuals with Parkinson's disease, Parkinson's disease dementia, Alzheimer's disease, and normal cognition. Phannarus H; Muangpaisan W; Siritipakorn P; Chotinaiwattarakul W Psychogeriatrics; 2020 Jan; 20(1):20-27. PubMed ID: 30912230 [TBL] [Abstract][Full Text] [Related]
9. COWAT Performance of Persons with Alzheimer Dementia, Vascular Dementia, and Parkinson Disease Dementia According to Stage of Cognitive Impairment. Lim KB; Kim J; Lee HJ; Yoo J; Kim HS; Kim C; Lee H PM R; 2019 Jul; 11(7):737-744. PubMed ID: 30746867 [TBL] [Abstract][Full Text] [Related]
10. Prevalence and severity of gait disorders in Alzheimer's and non-Alzheimer's dementias. Allan LM; Ballard CG; Burn DJ; Kenny RA J Am Geriatr Soc; 2005 Oct; 53(10):1681-7. PubMed ID: 16181166 [TBL] [Abstract][Full Text] [Related]
11. Cortical sources of resting state electroencephalographic rhythms in Parkinson's disease related dementia and Alzheimer's disease. Babiloni C; De Pandis MF; Vecchio F; Buffo P; Sorpresi F; Frisoni GB; Rossini PM Clin Neurophysiol; 2011 Dec; 122(12):2355-64. PubMed ID: 21924950 [TBL] [Abstract][Full Text] [Related]
12. Cognitive impairment in Parkinson's disease, Alzheimer's dementia, and vascular dementia: the role of the clock-drawing test. Allone C; Lo Buono V; Corallo F; Bonanno L; Palmeri R; Di Lorenzo G; Marra A; Bramanti P; Marino S Psychogeriatrics; 2018 Mar; 18(2):123-131. PubMed ID: 29417704 [TBL] [Abstract][Full Text] [Related]
13. The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients. Werber EA; Gandelman-Marton R; Klein C; Rabey JM J Neural Transm (Vienna); 2003 Jun; 110(6):659-69. PubMed ID: 12768361 [TBL] [Abstract][Full Text] [Related]
14. [Comparison of cognitive functions and neuropsychiatric symptoms between patients with Parkinson's disease dementia and Alzheimer's disease]. Tang Y; Ji XJ; Xing Y; Zuo XM; Zhou AH; Jia JP Zhonghua Yi Xue Za Zhi; 2013 Aug; 93(31):2459-62. PubMed ID: 24300264 [TBL] [Abstract][Full Text] [Related]
15. Cognitive MMN and P300 in mild cognitive impairment and Alzheimer's disease: A high density EEG-3D vector field tomography approach. Papadaniil CD; Kosmidou VE; Tsolaki A; Tsolaki M; Kompatsiaris IY; Hadjileontiadis LJ Brain Res; 2016 Oct; 1648(Pt A):425-433. PubMed ID: 27485659 [TBL] [Abstract][Full Text] [Related]
16. Auditory event-related potentials in Parkinson's disease: prominent correlation with attention. Matsui H; Nishinaka K; Oda M; Kubori T; Udaka F Parkinsonism Relat Disord; 2007 Oct; 13(7):394-8. PubMed ID: 17329143 [TBL] [Abstract][Full Text] [Related]
17. Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. Aarsland D; Cummings JL; Larsen JP Int J Geriatr Psychiatry; 2001 Feb; 16(2):184-91. PubMed ID: 11241724 [TBL] [Abstract][Full Text] [Related]
18. [Cognitive potential P300 in dementia with Levy's bodies and Alzheimer's disease]. Koberskaia NN; Zenkov LR; Zakharov VV; Preobrazhenskaia IS Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(1):61-4. PubMed ID: 15704487 [TBL] [Abstract][Full Text] [Related]
19. High-Density Lipoprotein Subclasses and Mild Cognitive Impairment: Study of Outcome and aPolipoproteins in Dementia (STOP-Dementia)1. Ohtani R; Nirengi S; Nakamura M; Murase N; Sainouchi M; Kuwata Y; Takata M; Masuda Y; Kotani K; Sakane N J Alzheimers Dis; 2018; 66(1):289-296. PubMed ID: 30248050 [TBL] [Abstract][Full Text] [Related]